BAM
LUCD icon

Berkshire Asset Management’s Lucid Diagnostics LUCD Stock Holding History

Berkshire Asset Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$20.2K – 282
2025
Q3 		$20.2K Hold
20,000
– – ﹤0.01% 297
2025
Q2 		$23K Hold
20,000
– – ﹤0.01% 285
2025
Q1 		$23.8K Buy
+20,000
New +$24K ﹤0.01% 281

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Asset Management's LUCD Position: Q4 2025 in Review

Berkshire Asset Management sold out of Lucid Diagnostics (LUCD) in Q4 2025, closing a stake of 20,000 shares — an estimated $20.2K sold.

Berkshire Asset Management first reported a position in LUCD in Q1 2025 and held it in 3 quarters. The position peaked at $23.8K in Q1 2025. 89 funds tracked by Wall St. Rank hold LUCD as of Q4 2025.

  • Berkshire Asset Management reported no remaining Lucid Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Berkshire Asset Management sold 20,000 Lucid Diagnostics shares in Q4 2025, an estimated $20.2K.
  • Berkshire Asset Management first reported a position in Lucid Diagnostics in Q1 2025 and held it in 3 quarters.
  • Berkshire Asset Management's Lucid Diagnostics position peaked at $23.8K in Q1 2025.
  • 89 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2025.

Based on Berkshire Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.